DE3751553D1 - Immunomodulare mittel und deren verwendung. - Google Patents

Immunomodulare mittel und deren verwendung.

Info

Publication number
DE3751553D1
DE3751553D1 DE3751553T DE3751553T DE3751553D1 DE 3751553 D1 DE3751553 D1 DE 3751553D1 DE 3751553 T DE3751553 T DE 3751553T DE 3751553 T DE3751553 T DE 3751553T DE 3751553 D1 DE3751553 D1 DE 3751553D1
Authority
DE
Germany
Prior art keywords
region
compositions
cells
relation
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE3751553T
Other languages
English (en)
Other versions
DE3751553T2 (de
Inventor
Malcolm Gefter
Jean-Gerard Guillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27360777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3751553(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of DE3751553D1 publication Critical patent/DE3751553D1/de
Publication of DE3751553T2 publication Critical patent/DE3751553T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE3751553T 1986-06-30 1987-06-26 Immunomodulare mittel und deren verwendung. Revoked DE3751553T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88013486A 1986-06-30 1986-06-30
US92428686A 1986-10-29 1986-10-29
US1734387A 1987-02-20 1987-02-20
PCT/US1987/001532 WO1988000057A1 (en) 1986-06-30 1987-06-26 Immunomodulating compositions and their use

Publications (2)

Publication Number Publication Date
DE3751553D1 true DE3751553D1 (de) 1995-11-09
DE3751553T2 DE3751553T2 (de) 1996-04-25

Family

ID=27360777

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751553T Revoked DE3751553T2 (de) 1986-06-30 1987-06-26 Immunomodulare mittel und deren verwendung.

Country Status (8)

Country Link
EP (1) EP0271577B1 (de)
JP (2) JP2633881B2 (de)
KR (1) KR880701108A (de)
AT (1) ATE128627T1 (de)
AU (1) AU603131B2 (de)
DE (1) DE3751553T2 (de)
DK (1) DK101888A (de)
WO (1) WO1988000057A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
JP2512796B2 (ja) † 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US6039947A (en) * 1987-06-24 2000-03-21 Autoimmune, Inc. Peptides derived from immunodominant epitopes of myelin basic protein
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
AU4030989A (en) * 1988-02-12 1989-09-06 Regents Of The University Of California, The Use of synthetic peptides to generate and manipulate cellular immunity
ATE130197T1 (de) * 1988-06-14 1995-12-15 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US6106840A (en) * 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5468481A (en) * 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US6077509A (en) * 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
DE69133516T2 (de) * 1990-10-15 2006-08-10 Autoimmune, Inc., Pasadena Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
EP1612555B1 (de) 1996-03-21 2008-10-22 Circassia Limited Verwendung von kryptischen Peptiden zur Induktion von immunologischer Toleranz
DE102011004335A1 (de) 2011-02-17 2012-08-23 Thomas Grammel Verfahren zur Herstellung eines Vakzins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0006916B1 (de) 1977-09-28 1981-07-08 National Research Development Corporation MHC-Antigene enthaltende immunologische Präparate und deren Herstellung
US4469677A (en) 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
US4565696A (en) 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4473555A (en) 1983-10-17 1984-09-25 Syntex (U.S.A.) Inc. Nona- and dodecapeptides for augmenting natural killer cell activity
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants

Also Published As

Publication number Publication date
AU603131B2 (en) 1990-11-08
DK101888A (da) 1988-04-26
JP2633881B2 (ja) 1997-07-23
EP0271577B1 (de) 1995-10-04
JP2828960B2 (ja) 1998-11-25
JPH01500595A (ja) 1989-03-01
EP0271577A1 (de) 1988-06-22
WO1988000057A1 (en) 1988-01-14
EP0271577A4 (de) 1990-01-08
KR880701108A (ko) 1988-07-25
AU7752487A (en) 1988-01-29
JPH09176042A (ja) 1997-07-08
DE3751553T2 (de) 1996-04-25
DK101888D0 (da) 1988-02-26
ATE128627T1 (de) 1995-10-15

Similar Documents

Publication Publication Date Title
DE3751553T2 (de) Immunomodulare mittel und deren verwendung.
DK614987D0 (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
TR199801722T2 (xx) Peptit imm�nojenler.
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ATE126706T1 (de) Hauttest und testkit für aids.
DE68925226D1 (de) Monoklonale Antikörper
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
EP0584715A3 (de) Gewinnung und Kultivierung transformierter Zellen und Herstellung gegen sie gerichteter Antikörper.
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
NO941370L (no) Rekombitope peptider
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
Hill et al. The effect of immunization of pigs with Ascaris suum cuticle components on the development of resistance to parenteral migration during a challenge infection
DE69738965D1 (de) Detoxifizierung durch intramuskulär verabreichte F(ab')2 Fragmente
DE3855280T2 (de) Von mca 16-88 erkanntes antigen
NO883603D0 (no) Humane monoklonale antistoffer og profylaktiske og terapeutiske midler mot infektioese sykdommer inneholdende disse som effektiv bestanddel.
ATE138200T1 (de) Das von mca-28a32 erkannte antigen
Beernink et al. Proteins adhering to Escherichia coli after exposure to guinea-pig serum
RU96123906A (ru) Способ и вакцина для профилактики и лечения иммунодефицитов, например рака
NO952506L (no) Antistoffpreparater mot homogent minaktivin og anvendelse derav for påvisning av minaktivin i humane kroppsvæsker

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation